![]() |
½ÃÀ庸°í¼
»óǰÄÚµå
1462761
¼¼°èÀÇ ¿µ»óÀ¯µµ ¹æ»ç¼±Ä¡·á(IGRT) ½ÃÀå Àü¸Á(-2030³â) : Á¦Ç°, ±â¼ú, ¿ëµµ, ÃÖÁ¾»ç¿ëÀÚ, Áö¿ªº° ºÐ¼®Image Guided Radiotherapy Market Forecasts to 2030 - Global Analysis By Product (Software, Hardware, Accessories and Service), Technology, Application, End User and By Geography |
Stratistics MRC¿¡ µû¸£¸é, ¼¼°è ¿µ»óÀ¯µµ ¹æ»ç¼±Ä¡·á(IGRT) ½ÃÀåÀº 2023³â 20¾ï 5,000¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú°í, ¿¹Ãø ±â°£ µ¿¾È 7.2%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 33¾ï 4,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
¿µ»óÀ¯µµ ¹æ»ç¼±Ä¡·á(IGRT, Image Guided Radiotherapy)´Â ¿µ»ó ±â¼úÀ» ÀÌ¿ëÇØ Á¾¾ç¿¡ ¹æ»ç¼±À» Á¶»çÇÏ´Â Á¤¹Ð ¹æ»ç¼± Ä¡·á·Î, ÀÓ»óÀǰ¡ Á¾¾ç°ú ÁÖº¯ Á¶Á÷À» ½Ç½Ã°£À¸·Î º¼ ¼ö ÀÖ¾î ¹æ»ç¼± Á¶»ç ½Ã °Ç°ÇÑ Á¶Á÷¿¡ ´ëÇÑ ¼Õ»óÀ» ÃÖ¼ÒÈÇÏ¸é¼ ¹æ»ç¼±À» º¸´Ù Á¤È®ÇÏ°Ô Ç¥ÀûÈÇÒ ¼ö ÀÖ½À´Ï´Ù. IGRT´Â Ä¡·á Áß ¿òÁ÷ÀÌ´Â Á¾¾çÀ̳ª Áß¿äÇÑ Àå±â ±Ùó¿¡ ÀÖ´Â Á¾¾ç¿¡ ƯÈ÷ È¿°úÀûÀ̸ç, Ä¡·á °á°ú¸¦ °³¼±Çϰí ȯÀÚÀÇ ¾ÈÀü¼ºÀ» Çâ»ó½ÃŰ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù.
¹Ì±¹¾ÏÇùȸ¿¡ µû¸£¸é Àü ¼¼°è ¾Ï ȯÀÚ ¼ö´Â 2040³â±îÁö 2,840¸¸ ¸í¿¡ ´ÞÇϰí, 2020³â ´ëºñ 47% Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, Àα¸ Åë°èÇÐÀû º¯È·Î ÀÎÇØ °³¹ßµµ»ó±¹¿¡¼ Áõ°¡°¡ µÎµå·¯Áö°í, ¾Ï ȯÀÚÀÇ 60% ÀÌ»óÀÌ Ä¡·áÀÇ ÀÏȯÀ¸·Î ¹æ»ç¼± Ä¡·á¸¦ ¹Þ°í ÀÖ½À´Ï´Ù.
¾ÏÀÇ À¯º´·ü Áõ°¡
¾Ï ¹ßº´·üÀÌ Áõ°¡ÇÔ¿¡ µû¶ó Á¤¹ÐÇÏ°í ´ú ħ½ÀÀûÀΠ÷´Ü Ä¡·á¹ý¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ÃÖ÷´Ü ¿µ»ó ±â¼úÀ» Ȱ¿ëÇÑ IGRT´Â °Ç°ÇÑ Á¶Á÷À» º¸Á¸ÇÏ¸é¼ Á¾¾çÀ» Á¤È®ÇÏ°Ô Á¶ÁØÇÒ ¼ö ÀÖ¾î ¾Ï Ä¡·á¿¡¼ Á¡Á¡ ´õ ¼±È£µÇ´Â Ä¡·á¹ýÀ¸·Î ÀÚ¸® Àâ°í ÀÖ½À´Ï´Ù. º¸´Ù È¿°úÀûÀÌ°í ¸ÂÃãÈµÈ ¾Ï Ä¡·á¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÔ¿¡ µû¶ó IGRT´Â ¸Å¿ì Áß¿äÇÑ ¼Ö·ç¼ÇÀ¸·Î ÀÚ¸®¸Å±èÇϰí ÀÖÀ¸¸ç, ¾Ï Ä¡·áÀÇ È®´ë¿¡ µû¶ó IGRTÀÇ µµÀÔ°ú ½ÃÀå ¼ºÀåÀÇ ¿øµ¿·ÂÀÌ µÇ°í ÀÖ½À´Ï´Ù.
¼÷·ÃµÈ Àü¹® Àη ºÎÁ·
ÈÆ·ÃµÈ Àü¹®°¡ÀÇ ºÎÁ·Àº ¿µ»óÀ¯µµ ¹æ»ç¼±Ä¡·á(IGRT) ½ÃÀå È®´ë¿¡ Å« °É¸²µ¹ÀÌ µÇ°í ÀÖÀ¸¸ç, IGRT ±â¼úÀ» ¼º°øÀûÀ¸·Î Ȱ¿ëÇÏ·Á¸é Á¶ÀÛ°ú ÇØ¼®¿¡ ´É¼÷ÇÑ ¼÷·ÃµÈ ÀÇ·áÁøÀÌ ÇÊ¿äÇÕ´Ï´Ù. ÀηÂÀÌ ÃæºÐÇÏÁö ¾ÊÀ¸¸é ÀÇ·á ½Ã¼³Àº IGRT ¼ºñ½º¸¦ Á¦°øÇÏ´Â µ¥ ¾î·Á¿òÀ» °ÞÀ» ¼ö ÀÖÀ¸¸ç, ÀÌ´Â IGRT ±â¼ú »ç¿ë ºÎÁ·À¸·Î À̾îÁ® ½ÃÀå ¼ºÀå ÀáÀç·ÂÀ» ÀúÇØÇÒ ¼ö ÀÖ½À´Ï´Ù.
¹æ»ç¼± Ä¡·á ÀåºñÀÇ ²÷ÀÓ¾ø´Â Çõ½Å
¹æ»ç¼± Ä¡·á ÀåºñÀÇ ²÷ÀÓ¾ø´Â ±â¼ú Çõ½ÅÀº Ä¡·áÀÇ Á¤È®¼º, È¿À²¼º ¹× ȯÀÚ °á°ú¸¦ Çâ»ó½Ãŵ´Ï´Ù. °³¼±µÈ ¿µ»ó ¾ç½Ä, ½Ç½Ã°£ ¸ð´ÏÅ͸µ, ÀÚµ¿ÈµÈ Ä¡·á Á¦°ø ½Ã½ºÅÛ°ú °°Àº °í±Þ ±â´ÉÀº ÁÖº¯ °Ç°ÇÑ Á¶Á÷ ¼Õ»óÀ» ÃÖ¼ÒÈÇÏ¸é¼ Á¾¾ç Ç¥Àû¿¡ ´ëÇÑ Á¤È®µµ¸¦ ³ôÀÔ´Ï´Ù. ÀÌ·¯ÇÑ ±â¼ú Çõ½ÅÀº ÃÖ÷´Ü ¼Ö·ç¼ÇÀ» ¿øÇÏ´Â ÀÇ·á ¼ºñ½º Á¦°ø¾÷ü¸¦ ²ø¾îµé¿© µµÀÔ·üÀ» ³ôÀ̰í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ±â¼úÀÇ ¹ßÀüÀ¸·Î º¸´Ù ÀÛ°í ºñ¿ë È¿À²ÀûÀÎ IGRT ½Ã½ºÅÛÀ» °³¹ßÇÒ ¼ö ÀÖ°Ô µÇ¾î ´õ ¸¹Àº ȯÀÚÃþ¿¡ ´ëÇÑ Á¢±Ù¼ºÀÌ È®´ëµÇ¾ú½À´Ï´Ù.
°í°¡ÀÇ Àåºñ¿Í Ä¡·áºñ¿ë
IGRTÀÇ ³ôÀº Àåºñ ¹× Ä¡·á ºñ¿ëÀ¸·Î ÀÎÇØ Á¢±Ù¼ºÀÌ Á¦ÇѵǸç, ƯÈ÷ ÀÇ·á ¿¹»êÀÌ Á¦ÇÑµÈ Áö¿ª¿¡¼´Â IGRT ½Ã½ºÅÛ¿¡ ÇÊ¿äÇÑ ¸·´ëÇÑ Ãʱâ ÅõÀÚ ¹× Áö¼ÓÀûÀÎ Ä¡·á ºñ¿ëÀ¸·Î ÀÎÇØ ÀÇ·á ±â°üÀÌ ÀÌ ±â¼úÀ» äÅÃÇÏ´Â °ÍÀ» ÁÖÀúÇÏ°Ô µË´Ï´Ù. ¶ÇÇÑ È¯ÀÚ´Â °æÁ¦Àû ºÎ´ã¿¡ Á÷¸éÇϰí ÀÇ·á ¼ºñ½º Á¦°ø¾÷ü´Â IGRT ½Ã¼ú¿¡ ´ëÇÑ »óȯÀ» º¸ÀåÇÏ´Â µ¥ ¾î·Á¿òÀ» °Þ½À´Ï´Ù. °á°úÀûÀ¸·Î ³ôÀº Àåºñ ¹× Ä¡·á ºñ¿ëÀ¸·Î ÀÎÇØ IGRTÀÇ º¸±Þ°ú ÀÌ¿ëÀÌ ÀúÇØµÇ¾î ½ÃÀå È®´ë¸¦ ÀúÇØÇϰí ÀÖ½À´Ï´Ù.
COVID-19ÀÇ ¿µÇâ
Äڷγª19´Â ¿µ»óÀ¯µµ ¹æ»ç¼±Ä¡·á(IGRT) ½ÃÀå¿¡ ´Ù¾çÇÑ ¿µÇâÀ» ¹ÌÃÆ½À´Ï´Ù. Ãʱ⿡´Â ÀÇ·á ½Ã¼³ÀÇ Æó¼â¿Í ÀÚ¿øÀÇ ¿ì¼±¼øÀ§ ÀçÁ¶Á¤À¸·Î ÀÎÇØ Ä¡·á ÀÏÁ¤¿¡ Â÷ÁúÀÌ »ý±â°í ½Å±Ô Àåºñ µµÀÔÀÌ µÐȵÆÀ¸³ª, ÀÌÈÄ È°¹ßÇÑ ¼ö¿ä¿Í ¾Ï Ä¡·á¿¡ ´ëÇÑ °ü½É Áõ°¡·Î ÀÎÇØ ȸº¹¼¼¸¦ º¸À̰í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÆÒµ¥¹ÍÀº ¿ø°Ý ÀÇ·á ¹× ¿ø°Ý ¸ð´ÏÅ͸µ ±â¼úÀÇ Ã¤ÅÃÀ» °¡¼ÓÈÇϰí ÀÖÀ¸¸ç, ÀÌ´Â IGRT ¼ºñ½º Á¦°ø ¹× Á¢±Ù ¹æ½Ä¿¡ Àå±âÀûÀÎ ¿µÇâÀ» ¹ÌÄ¡°í ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ ¼ö ÀÖ½À´Ï´Ù.
¿¹Ãø ±â°£ µ¿¾È 3D ÃÊÀ½ÆÄ ºÐ¾ß°¡ °¡Àå Å« ºÐ¾ß°¡ µÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
3D ÃÊÀ½ÆÄ´Â Á¾¾ç ºÎÀ§¸¦ ½Ç½Ã°£À¸·Î °íÇØ»óµµ À̹ÌÁöÈÇÏ¿© Ä¡·áÀÇ Á¤È®¼º°ú Á¤¹Ðµµ¸¦ Çâ»ó½ÃŰ´Â 3D ÃÊÀ½ÆÄ ºÎ¹®Àº À¯¸®ÇÑ ¼ºÀå¼¼¸¦ º¸ÀÏ °ÍÀ¸·Î ÃßÁ¤µË´Ï´Ù. ÀÌ ±â¼úÀº Á¾¾çÀÇ °æ°è¿Í ÁÖº¯ ÇØºÎÇÐÀû ±¸Á¶¸¦ ´õ Àß º¼ ¼ö ÀÖ¾î Á¾¾ç Àü¹®Àǰ¡ ¹æ»ç¼± Ä¡·á¸¦ ¸Å¿ì Á¤È®ÇÏ°Ô Á¶Á¤ÇÒ ¼ö ÀÖÀ¸¸ç, IGRT ¿öÅ©Ç÷ο쿡 ÅëÇÕÇϸé ȯÀÚ °á°ú¿Í Ä¡·á È¿°ú¸¦ Çâ»ó½Ãų ¼ö ÀÖ½À´Ï´Ù.
¿¹Ãø ±â°£ µ¿¾È ³úÁ¾¾ç ºÐ¾ß´Â °¡Àå ³ôÀº CAGRÀ» ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
³úÁ¾¾ç ºÐ¾ß´Â ¿¹Ãø ±â°£ µ¿¾È °¡Àå ³ôÀº CAGR ¼ºÀåÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹»óµÇ¸ç, IGRT´Â MRI, CT, PET ½ºÄµ°ú °°Àº ÷´Ü ¿µ»ó Áø´Ü ±â¼úÀ» Ȱ¿ëÇÏ¿© Ä¡·á ÁßÀÎ Á¾¾çÀ» ½Ç½Ã°£À¸·Î ½Ã°¢ÈÇÏ¿© Á¤È®ÇÑ ¹æ»ç¼± Á¶»ç°¡ °¡´ÉÇϵµ·Ï ÇÕ´Ï´Ù. À̸¦ ÅëÇØ ºÎÀÛ¿ëÀÇ À§ÇèÀ» ÁÙÀÌ¸é¼ Ä¡·á È¿°ú¸¦ ³ôÀÏ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ȯÀÚ °³°³ÀÎÀÇ Çʿ信 µû¶ó ¸ÂÃã Ä¡·á °èȹÀ» ½±°Ô ¼ö¸³ÇÒ ¼ö ÀÖ¾î ³úÁ¾¾ç ȯÀÚÀÇ Ä¡·á °á°ú¸¦ ÃÖÀûÈÇÒ ¼ö ÀÖ½À´Ï´Ù.
¾Æ½Ã¾ÆÅÂÆò¾çÀº ¾Ï ¹ßº´·ü Áõ°¡¿Í ÀÇ·á ÀÎÇÁ¶óÀÇ ¹ßÀüÀ¸·Î ÀÎÇØ ¿¹Ãø ±â°£ µ¿¾È °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. Áß±¹°ú Àεµ¿Í °°Àº ½ÅÈï±¹Àº ÀÇ·áºñ Áõ°¡¿Í ÷´Ü Ä¡·á¹ý¿¡ ´ëÇÑ Á¢±Ù¼º È®´ë¿¡ ÈûÀÔ¾î ÁÖ¿ä ±â¿©±¹À¸·Î ºÎ»óÇϰí ÀÖ½À´Ï´Ù. ¾çÈ£ÇÑ ±ÔÁ¦ ȯ°æ°ú ¾Ï Ä¡·á¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁü¿¡ µû¶ó ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ IGRT ½ÃÀåÀº Áö¼ÓÀûÀ¸·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
À¯·´Àº ³ôÀº ¾Ï ¹ßº´·ü°ú źźÇÑ ÀÇ·á ÀÎÇÁ¶ó¸¦ ¹ÙÅÁÀ¸·Î ¿¹Ãø ±â°£ µ¿¾È °¡Àå ³ôÀº CAGRÀ» ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¹Ì±¹Àº ±¤¹üÀ§ÇÑ R&D Ȱµ¿°ú ÇコÄÉ¾î ±â¼ú¿¡ ´ëÇÑ ¸·´ëÇÑ ÅõÀÚ·Î ½ÃÀåÀ» ÁÖµµÇϰí ÀÖ½À´Ï´Ù. ÷´Ü ¿µ»ó ±â¼ú ¹× ¼ÒÇÁÆ®¿þ¾î ¼Ö·ç¼ÇÀÇ Ã¤ÅÃÀÌ Áõ°¡Çϰí ÀÖÀ¸¸ç, À¯¸®ÇÑ »óȯ Á¤Ã¥À¸·Î ÀÎÇØ ½ÃÀå È®´ë°¡ ÃËÁøµÇ°í ÀÖ½À´Ï´Ù. ºÏ¹Ì IGRT ½ÃÀåÀº Á¤¹ÐÀÇ·á¿Í ȯÀÚ Áß½É Ä¡·á¿¡ ÁßÁ¡À» µÎ°í Áö¼ÓÀûÀÎ ¼ºÀå°ú ±â¼ú ¹ßÀüÀ» ÀÌ·ê ¼ö ÀÖ´Â ¿©°ÇÀ» °®Ãß°í ÀÖ½À´Ï´Ù.
According to Stratistics MRC, the Global Image Guided Radiotherapy Market is accounted for $2.05 billion in 2023 and is expected to reach $3.34 billion by 2030 growing at a CAGR of 7.2% during the forecast period. Image Guided Radiotherapy (IGRT) is a precise form of radiation therapy that utilizes imaging technology to guide the delivery of radiation to tumours. IGRT enables clinicians to visualize the tumor and surrounding tissues in real-time, allowing for more accurate targeting of radiation and minimizing damage to healthy tissue. This approach enhances treatment effectiveness while reducing side effects. IGRT is particularly valuable for tumours that move during treatment or are located near critical organs, offering improved outcomes and increased patient safety.
According to the American Cancer Society, the burden of cancer worldwide is expected to reach ~28.4 million cases by 2040, increased by 47% from 2020, with greater increases in developing countries due to demographic changes and over 60% of cancer patients undergo some form of radiation therapy as part of their treatment.
Rising prevalence of cancer
With cancer incidence rates on the rise, there's an amplified demand for advanced treatment modalities that offer precision and minimal invasiveness. IGRT, leveraging cutting-edge imaging technologies, enables precise tumor targeting while sparing healthy tissues, making it an increasingly preferred option in oncology. This growing demand for more effective and tailored cancer treatments positions IGRT as a pivotal solution, driving its adoption and market growth amidst the expanding landscape of cancer care.
Lack of skilled professionals
The scarcity of trained professionals poses a significant obstacle to the expansion of the Image Guided Radiotherapy (IGRT) market. Successful utilization of IGRT technology necessitates skilled healthcare practitioners proficient in its operation and interpretation. Without an adequate workforce, healthcare facilities may struggle to offer IGRT services, leading to underutilization of IGRT technology and hindering its market growth potential.
Continuous innovations in radiotherapy equipment
Continuous innovations in radiotherapy equipment enhance treatment precision, efficiency, and patient outcomes. Advanced features such as improved imaging modalities, real-time monitoring, and automated treatment delivery systems increase the accuracy of tumor targeting while minimizing damage to surrounding healthy tissue. These innovations attract healthcare providers seeking state-of-the-art solutions, boosting adoption rates. Additionally, technological advancements enable the development of more compact and cost-effective IGRT systems, expanding accessibility to a broader patient population.
High cost of equipment and treatment
The high cost of equipment and treatment in IGRT limits accessibility, particularly in regions with constrained healthcare budgets. The substantial initial investment required for IGRT systems and ongoing treatment expenses can deter healthcare facilities from adopting this technology. Additionally, patients face financial burdens, and healthcare providers encounters challenges in securing reimbursement for IGRT procedures. Consequently, the high cost of equipment and treatment hampers the widespread adoption and utilization of IGRT, impeding market expansion.
Covid-19 Impact
The covid-19 pandemic has had a mixed impact on the image guided radiotherapy market. While it initially led to disruptions in treatment schedules and a slowdown in installations of new equipment due to healthcare facility closures and reprioritization of resources, there has been a subsequent rebound driven by pent-up demand and a growing emphasis on cancer care. Furthermore, the pandemic has accelerated the adoption of telemedicine and remote monitoring technologies, which could have long-term implications for how IGRT services are delivered and accessed, potentially fostering market growth.
The 3D ultrasound segment is expected to be the largest during the forecast period
The 3D ultrasound segment is estimated to have a lucrative growth. By providing real-time, high-resolution imaging of tumor sites, 3D ultrasound enhances the precision and accuracy of treatment delivery. This technology allows for better visualization of tumor boundaries and surrounding anatomy, enabling oncologists to tailor radiation therapy with utmost precision. Its incorporation into IGRT workflows enhances patient outcomes and treatment efficacy.
The brain tumours segment is expected to have the highest CAGR during the forecast period
The brain tumours segment is anticipated to witness the highest CAGR growth during the forecast period. Utilizing advanced imaging techniques such as MRI, CT, and PET scans, IGRT enables real-time visualization of tumours during treatment, allowing for accurate radiation delivery. This approach enhances treatment efficacy while reducing the risk of side effects. It also facilitates personalized treatment plans tailored to individual patient needs, optimizing outcomes for brain tumor patients.
Asia Pacific is projected to hold the largest market share during the forecast period owing to increasing cancer incidence and advancements in healthcare infrastructure. Emerging economies such as China and India are key contributors, supported by rising healthcare expenditure and expanding access to advanced treatment modalities. With a favourable regulatory environment and growing awareness about cancer care, the Asia Pacific IGRT market is poised for continued growth.
Europe is projected to have the highest CAGR over the forecast period, owing to high prevalence of cancer and robust healthcare infrastructure. The United States dominates the market, driven by extensive research and development activities, along with significant investments in healthcare technology. Increasing adoption of advanced imaging technologies and software solutions, coupled with favourable reimbursement policies, propels market expansion. With a focus on precision medicine and patient-centric care, the North American IGRT market is poised for sustained growth and technological advancements.
Key players in the market
Some of the key players profiled in the Image Guided Radiotherapy Market include Siemens Healthineers, Elekta AB, Accuray Incorporated, ViewRay, Inc., Brainlab AG, RaySearch Laboratories, Mevion Medical Systems, C-RAD AB, IBA Dosimetry GmbH, Philips Healthcare, Hitachi Medical Systems, Theragenics Corporation, Nanobiotix and Xstrahl Limited.
In March 2024, Siemens Healthineers and Varian Medical Systems announced the launch of their Image Guided Radiotherapy (IGR) product. The product helps practitioners provide digital image data for diagnosis, risk stratification, and treatment planning in the early stages of liver cancer detection. The data can also provide guidance and support during care.
In February 2024, Royal Philips, a health technology company, announced the launch of the Azurion neuro biplane system, a new version of its Image Guided Therapy (IGT) platform. The Azurion platform is powered by ConnectOS, a new operating system from Philips that optimizes system integration.